Published in Eur Heart J on October 21, 2010
Niacin Plus Statin to Prevent Vascular Events | NCT00120289
High Intensity Interval Training: Physiological Adaptation and Intervention Fidelity | NCT03700671
Lipid-related markers and cardiovascular disease prediction. JAMA (2012) 3.91
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J (2013) 3.58
Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2014) 3.48
Genetic associations with valvular calcification and aortic stenosis. N Engl J Med (2013) 3.02
Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Circulation (2013) 3.02
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J (2011) 3.00
The Treatment of Disorders of Lipid Metabolism. Dtsch Arztebl Int (2016) 2.91
Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation (2011) 1.90
Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey. Drug Des Devel Ther (2011) 1.68
Genetic variants in PLG, LPA, and SIGLEC 14 as well as smoking contribute to plasma plasminogen levels. Blood (2014) 1.51
Dyslipidaemia: PCSK9 antibodies: a dividend of the genomics revolution. Nat Rev Cardiol (2013) 1.44
Lipid parameters for measuring risk of cardiovascular disease. Nat Rev Cardiol (2011) 1.43
Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J (2015) 1.28
Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). J Am Coll Cardiol (2013) 1.23
Genetic variants, plasma lipoprotein(a) levels, and risk of cardiovascular morbidity and mortality among two prospective cohorts of type 2 diabetes. Eur Heart J (2011) 1.20
Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a). J Lipid Res (2012) 1.17
Dietary and Policy Priorities for Cardiovascular Disease, Diabetes, and Obesity: A Comprehensive Review. Circulation (2016) 1.13
Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS One (2012) 1.10
Lipoprotein(a) metabolism: potential sites for therapeutic targets. Metabolism (2012) 1.08
Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities. Br J Pharmacol (2012) 1.07
Nonfasting glucose, ischemic heart disease, and myocardial infarction: a Mendelian randomization study. J Am Coll Cardiol (2012) 1.06
Oxidation-specific epitopes and immunological responses: Translational biotheranostic implications for atherosclerosis. Curr Opin Pharmacol (2013) 1.06
Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care (2012) 0.97
Race is a key variable in assigning lipoprotein(a) cutoff values for coronary heart disease risk assessment: the Multi-Ethnic Study of Atherosclerosis. Arterioscler Thromb Vasc Biol (2015) 0.97
Emerging risk factors for cardiovascular diseases: Indian context. Indian J Endocrinol Metab (2013) 0.97
New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs. Eur Heart J (2013) 0.96
Farnesoid X receptor represses hepatic human APOA gene expression. J Clin Invest (2011) 0.94
Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials. Arterioscler Thromb Vasc Biol (2015) 0.92
Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension. Eur Heart J (2013) 0.92
Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans. Circulation (2016) 0.91
Association between low-dose folic acid supplementation and blood lipids concentrations in male and female subjects with atherosclerosis risk factors. Med Sci Monit (2013) 0.91
Low lipoprotein(a) concentration is associated with cancer and all-cause deaths: a population-based cohort study (the JMS cohort study). PLoS One (2012) 0.89
PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role. J Lipid Res (2016) 0.88
Lipoprotein(a) and SYNTAX Score Association with Severity of Coronary Artery Atherosclerosis in North India. Sultan Qaboos Univ Med J (2012) 0.87
Peroxisome Proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression. J Biol Chem (2012) 0.87
Elevated oxidative stress among coronary artery disease patients on statin therapy: A cross sectional study. Indian Heart J (2015) 0.87
Lipoprotein (a) concentrations, apolipoprotein (a) phenotypes, and peripheral arterial disease in three independent cohorts. Cardiovasc Res (2014) 0.87
Measurement of apo(a) kinetics in human subjects using a microfluidic device with tandem mass spectrometry. Rapid Commun Mass Spectrom (2013) 0.86
Human Genetics and the Causal Role of Lipoprotein(a) for Various Diseases. Cardiovasc Drugs Ther (2016) 0.86
Niacin: another look at an underutilized lipid-lowering medication. Nat Rev Endocrinol (2012) 0.86
Racial and Ethnic Variation in Lipoprotein (a) Levels among Asian Indian and Chinese Patients. J Lipids (2011) 0.86
Lipoprotein (a): structure, pathophysiology and clinical implications. Arq Bras Cardiol (2014) 0.86
AGE-Related Differences of Novel Atherosclerotic Risk Factors and Angiographic Profile Among Gujarati Acute Coronary Syndrome Patients. J Clin Diagn Res (2015) 0.85
Profile of evolocumab and its potential in the treatment of hyperlipidemia. Drug Des Devel Ther (2015) 0.85
Four-year analysis of cardiovascular disease risk factors, depression symptoms, and antidepressant medicine use in the Look AHEAD (Action for Health in Diabetes) clinical trial of weight loss in diabetes. Diabetes Care (2013) 0.85
Lipoprotein(a): genotype-phenotype relationship and impact on atherogenic risk. Metab Syndr Relat Disord (2011) 0.85
Lipoprotein(a) Interactions With Low-Density Lipoprotein Cholesterol and Other Cardiovascular Risk Factors in Premature Acute Coronary Syndrome (ACS). J Am Heart Assoc (2016) 0.85
Cardiometabolic changes and disparities among persons with spinal cord injury: a 17-year cohort study. Top Spinal Cord Inj Rehabil (2014) 0.85
Lipoprotein (a) measurements for clinical application. J Lipid Res (2015) 0.84
Low-density lipoprotein cholesterol, apolipoprotein B, and risk of coronary heart disease: from familial hyperlipidemia to genomics. Biol Res Nurs (2012) 0.84
HIV disease activity as a modulator of lipoprotein(a) and allele-specific apolipoprotein(a) levels. Arterioscler Thromb Vasc Biol (2012) 0.84
Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Br J Clin Pharmacol (2014) 0.84
Oxidation-specific epitopes as targets for biotheranostic applications in humans: biomarkers, molecular imaging and therapeutics. Curr Opin Lipidol (2013) 0.83
Lack of association between four SNPs in the SLC22A3-LPAL2-LPA gene cluster and coronary artery disease in a Chinese Han population: a case control study. Lipids Health Dis (2012) 0.83
Lipoprotein(a): a promising marker for residual cardiovascular risk assessment. Dis Markers (2013) 0.83
Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. J Lipid Res (2016) 0.83
Lipoprotein(a) in cardiovascular diseases. Biomed Res Int (2012) 0.83
Meta analysis of candidate gene variants outside the LPA locus with Lp(a) plasma levels in 14,500 participants of six White European cohorts. Atherosclerosis (2011) 0.83
Preventing and Experiencing Ischemic Heart Disease as a Woman: State of the Science: A Scientific Statement From the American Heart Association. Circulation (2016) 0.83
Association between the interleukin-6 promoter polymorphism -174G/C and serum lipoprotein(a) concentrations in humans. PLoS One (2011) 0.82
Hierarchical modelling of blood lipids' profile and 10-year (2002-2012) all cause mortality and incidence of cardiovascular disease: the ATTICA study. Lipids Health Dis (2015) 0.82
Oxidized lipoprotein(a) and cardio-ankle vascular index (CAVI) in hypertensive subjects. Heart Vessels (2012) 0.82
Impact of L-carnitine on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled trials. Sci Rep (2016) 0.82
Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice. J Lipid Res (2012) 0.82
Heritability of Biomarkers of Oxidized Lipoproteins: Twin Pair Study. Arterioscler Thromb Vasc Biol (2015) 0.82
Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia. J Lipid Res (2012) 0.81
Impact of the German Lipoprotein Apheresis Registry (DLAR) on therapeutic options to reduce increased Lp(a) levels. Clin Res Cardiol Suppl (2015) 0.81
Insulin resistance, dyslipidemia and cardiovascular changes in a group of obese children. Arq Bras Cardiol (2015) 0.81
A Systematic Literature Review of the Association of Lipoprotein(a) and Autoimmune Diseases and Atherosclerosis. Int J Rheumatol (2012) 0.81
Relook at lipoprotein (A): independent risk factor of coronary artery disease in north Indian population. Indian Heart J (2014) 0.81
Elevated lipoprotein(a) levels predict cardiovascular disease in type 2 diabetes mellitus: a 10-year prospective cohort study. Korean J Intern Med (2016) 0.81
Ideal cardiovascular health influences cardiovascular disease risk associated with high lipoprotein(a) levels and genotype: The EPIC-Norfolk prospective population study. Atherosclerosis (2016) 0.81
Lipoprotein(a) and cardiovascular disease in diabetic patients. Clin Lipidol (2012) 0.81
Niacin, an old drug with a new twist. J Lipid Res (2013) 0.81
Lipoprotein(a) for risk assessment in patients with established coronary artery disease. J Am Coll Cardiol (2013) 0.80
Serum Galectin-9 Levels Are Associated with Coronary Artery Disease in Chinese Individuals. Mediators Inflamm (2015) 0.80
High levels of lipoprotein(a) are associated with a lower prevalence of diabetes with advancing age: results of a cross-sectional epidemiological survey in Gran Canaria, Spain. Cardiovasc Diabetol (2012) 0.80
Inhibition of plasminogen activation by apo(a): role of carboxyl-terminal lysines and identification of inhibitory domains in apo(a). J Lipid Res (2014) 0.80
The year in cardiology 2015: prevention. Eur Heart J (2016) 0.79
The genetics of familial hypercholesterolemia and emerging therapies. Appl Clin Genet (2015) 0.79
Lp(a) is not associated with diabetes but affects fibrinolysis and clot structure ex vivo. Sci Rep (2014) 0.79
Carotid Intima-Media Thickness in Asymptomatic Subjects With Low Lipoprotein(a) Levels. J Clin Med Res (2012) 0.79
Monocyte subset distribution in patients with stable atherosclerosis and elevated levels of lipoprotein(a). J Clin Lipidol (2015) 0.79
Significant associations between lipoprotein(a) and corrected apolipoprotein B-100 levels in African-Americans. Atherosclerosis (2014) 0.79
Lipoprotein (a) upregulates ABCA1 in liver cells via scavenger receptor-B1 through its oxidized phospholipids. J Lipid Res (2015) 0.78
Association of lipoprotein subfractions and coronary artery calcium in patient at intermediate cardiovascular risk. Am J Cardiol (2012) 0.78
Healthy dietary interventions and lipoprotein (a) plasma levels: results from the Omni Heart Trial. PLoS One (2014) 0.78
Lipoprotein (a)-We Know So Much Yet Still Have Much to Learn …. J Am Heart Assoc (2016) 0.78
Relationship between Lipoprotein(a) and Thyroid Hormones in Hypothyroid Patients. J Clin Diagn Res (2014) 0.78
Lipoprotein (a): Coming of Age at Last. J Lipid Res (2016) 0.78
Baseline LDL-C and Lp(a) elevations portend a high risk of coronary revascularization in patients after stent placement. Dis Markers (2013) 0.77
Lipoprotein(a) is associated with necrotic core progression of non-culprit coronary lesions in statin-treated patients with angina pectoris. Lipids Health Dis (2014) 0.77
Statins for primary prevention: problems with cardiovascular-risk estimation? Nat Rev Cardiol (2013) 0.77
A comparative study on serum lipoprotein (a) and lipid profile between rheumatoid arthritis patients and normal subjects. J Pharm Bioallied Sci (2015) 0.77
The effect of genetic variation in PCSK9 on the LDL-cholesterol response to statin therapy. Pharmacogenomics J (2016) 0.77
Lipoprotein(a)-clinical aspects and future challenges. Clin Res Cardiol Suppl (2015) 0.77
Correlation between serum levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery disease. Lipids Health Dis (2016) 0.77
Current therapies for lowering lipoprotein (a). J Lipid Res (2015) 0.77
Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med (2009) 9.35
Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med (2009) 8.73
Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med (1990) 6.43
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol (1986) 6.27
Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA (2009) 5.63
Mendelian randomization: prospects, potentials, and limitations. Int J Epidemiol (2004) 5.07
Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA (2009) 4.42
Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med (2005) 4.16
Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med (2010) 3.17
Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. Circulation (1999) 3.08
Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation (2000) 3.05
Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand (1988) 2.86
Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease. N Engl J Med (1998) 2.81
European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil (2007) 2.70
A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. Arterioscler Thromb Vasc Biol (2007) 2.47
Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA (1990) 2.36
Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol (2010) 2.20
Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation (2007) 2.07
Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data. Arch Intern Med (2008) 2.01
Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study. J Am Coll Cardiol (1998) 1.88
Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk. J Am Coll Cardiol (2001) 1.80
Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA (1995) 1.74
Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions. Clin Chem (2003) 1.74
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Arterioscler Thromb Vasc Biol (2004) 1.70
Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events. J Am Coll Cardiol (2008) 1.69
Ethnic differences in cardiovascular risk factor burden among middle-aged women: Study of Women's Health Across the Nation (SWAN). Am Heart J (2005) 1.67
Recommendations for the use of LDL apheresis. Atherosclerosis (2008) 1.65
Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice. Circulation (2008) 1.55
New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease. Arterioscler Thromb Vasc Biol (2007) 1.42
Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study. Atherosclerosis (2002) 1.41
Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis (2009) 1.36
Structure-function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity. Curr Opin Lipidol (2004) 1.20
Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol Ther (2010) 1.18
The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate. J Clin Invest (1994) 1.14
Lipoprotein(a) in atherosclerotic plaques recruits inflammatory cells through interaction with Mac-1 integrin. FASEB J (2006) 1.12
Lipoprotein(a) impairs generation of plasmin by fibrin-bound tissue-type plasminogen activator. In vitro studies in a plasma milieu. Arterioscler Thromb (1991) 1.09
Modification of apolipoprotein(a) lysine binding site reduces atherosclerosis in transgenic mice. J Clin Invest (1997) 1.02
The effect of vascular smooth muscle cell-targeted expression of tissue factor pathway inhibitor in a murine model of arterial thrombosis. Thromb Haemost (2004) 1.01
Defensin promotes the binding of lipoprotein(a) to vascular matrix. Blood (1999) 1.01
Atherogenecity of lipoprotein(a) and oxidized low density lipoprotein: insight from in vivo studies of arterial wall influx, degradation and efflux. Atherosclerosis (1999) 0.99
Atorvastatin lowers lipoprotein(a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk. Atherosclerosis (2002) 0.98
Does elevated C-reactive protein cause human atherothrombosis? Novel insights from genetics, intervention trials, and elsewhere. Curr Opin Lipidol (2009) 0.98
Apolipoprotein(a) inhibits the conversion of Glu-plasminogen to Lys-plasminogen: a novel mechanism for lipoprotein(a)-mediated inhibition of plasminogen activation. J Thromb Haemost (2008) 0.97
Lipoprotein(a) is an independent risk factor for cardiovascular disease in heterozygous familial hypercholesterolemia. Clin Chem (2005) 0.95
Lipoprotein a: where are we now? Curr Opin Cardiol (2009) 0.92
Proteoglycans contribution to association of Lp(a) and LDL with smooth muscle cell extracellular matrix. Arterioscler Thromb Vasc Biol (1999) 0.90
Does apolipoprotein(a) heterogeneity influence lipoprotein(a) effects on fibrinolysis? Blood (1993) 0.87
Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science (2007) 51.70
Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet (2008) 20.73
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73
Guidelines on the management of valvular heart disease (version 2012). Eur Heart J (2012) 10.70
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J (2011) 10.52
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J (2013) 9.54
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil (2007) 6.10
Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg (2012) 5.49
Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol (2012) 5.12
Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet (2012) 4.63
Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation (2007) 4.62
Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med (2014) 4.41
Common missense variant in the glucokinase regulatory protein gene is associated with increased plasma triglyceride and C-reactive protein but lower fasting glucose concentrations. Diabetes (2008) 4.20
Short telomere length, cancer survival, and cancer risk in 47102 individuals. J Natl Cancer Inst (2013) 3.92
Comparison of intravenous alteplase with a combined intravenous-endovascular approach in patients with stroke and confirmed arterial occlusion (RECANALISE study): a prospective cohort study. Lancet Neurol (2009) 3.88
Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet (2013) 3.87
Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation (2013) 3.80
Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature (2002) 3.80
SNARE proteins mediate fusion between cytosolic lipid droplets and are implicated in insulin sensitivity. Nat Cell Biol (2007) 3.69
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J (2013) 3.58
A transient ischaemic attack clinic with round-the-clock access (SOS-TIA): feasibility and effects. Lancet Neurol (2007) 3.56
Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med (2011) 3.52
Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol (2003) 3.26
Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev (2006) 3.26
Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS One (2010) 3.15
Visible age-related signs and risk of ischemic heart disease in the general population: a prospective cohort study. Circulation (2013) 3.09
Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet (2011) 3.07
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J (2011) 3.00
Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes. Diabetes (2005) 2.99
Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol (2008) 2.96
ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis (2011) 2.90
Addition of brain and carotid imaging to the ABCD² score to identify patients at early risk of stroke after transient ischaemic attack: a multicentre observational study. Lancet Neurol (2010) 2.87
Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1). Nat Genet (2004) 2.86
Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology (2015) 2.81
One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care (2009) 2.75
A review of the evidence for the use of telemedicine within stroke systems of care: a scientific statement from the American Heart Association/American Stroke Association. Stroke (2009) 2.74
Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care (2008) 2.73
European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil (2007) 2.70
Genetic variant of the scavenger receptor BI in humans. N Engl J Med (2011) 2.69
The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol (2013) 2.60
The gut microbiota modulates host energy and lipid metabolism in mice. J Lipid Res (2009) 2.59
Lipoprotein lipase S447X: a naturally occurring gain-of-function mutation. Arterioscler Thromb Vasc Biol (2006) 2.55
Atherosclerotic disease of the aortic arch as a risk factor for recurrent ischemic stroke. The French Study of Aortic Plaques in Stroke Group. N Engl J Med (1996) 2.55
Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med (2006) 2.55
ApoE regulates hematopoietic stem cell proliferation, monocytosis, and monocyte accumulation in atherosclerotic lesions in mice. J Clin Invest (2011) 2.54
Statin treatment and stroke outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke (2009) 2.51
Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function. Arterioscler Thromb Vasc Biol (2009) 2.50
New England Medical Center Posterior Circulation registry. Ann Neurol (2004) 2.42
Association of plasma uric acid with ischaemic heart disease and blood pressure: mendelian randomisation analysis of two large cohorts. BMJ (2013) 2.41
New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol (2012) 2.41
Requirement of JNK2 for scavenger receptor A-mediated foam cell formation in atherogenesis. Science (2004) 2.38
Complete rescue of lipoprotein lipase-deficient mice by somatic gene transfer of the naturally occurring LPLS447X beneficial mutation. Arterioscler Thromb Vasc Biol (2005) 2.36
Intracranial arterial dolichoectasia and small-vessel disease in stroke patients. Ann Neurol (2005) 2.36
HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem (2011) 2.33
Mobilization of bone marrow-derived stem cells after myocardial infarction and left ventricular function. Eur Heart J (2005) 2.33
Extreme bilirubin levels as a causal risk factor for symptomatic gallstone disease. JAMA Intern Med (2013) 2.30
Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost (2014) 2.29
Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol (2007) 2.29
Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care (2005) 2.26
Recommendations for the implementation of telemedicine within stroke systems of care: a policy statement from the American Heart Association. Stroke (2009) 2.26
Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol (2007) 2.22
Intracranial arterial dolichoectasia and its relation with atherosclerosis and stroke subtype. Neurology (2003) 2.22
[ESC/EAS Guidelines for the management of dyslipidaemias]. Rev Esp Cardiol (2011) 2.21